Clinical study of diagnostic method for dementia using samples from nasal cavity (1) - study on sampling sites and pre-treatment methods -

Clinical study of diagnostic method for dementia using samples from nasal cavity (1) - study on sampling sites and pre-treatment methods - - Clinical study of diagnostic method for dementia using samples from nasal cavity (1)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000014117

Enrollment

Registered

2014-06-01

Start date

2014-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with Alzheimer' s disease and control cases are selected by clinical symptoms, psychological tests and imaging used in J-ADNI study. 2. More than 60-year-old. 3. Informed consent by the patient or guardian.

Exclusion criteria

Exclusion criteria: 1. People having nose disease such as sinusitis and allergic rhinitis. 2. People with bleeding tendency. 3. People who can not take MRI examination. 4. Patients who were judged inappropriate for this study by the investigator.

Design outcomes

Primary

Measure	Time frame
Assessments of effectiveness: Using samples from nasal cavity of patients of Alzheimer's disease and normal control; 1. Determine sampling sites such as olfactory cleft, middle nasal meatus, inferior nasal concha, and common nasal meatus for comparing AD patients with controls. 2. Examine a possibility of simultaneous detection of Abeta and tau with pretreatment method developed by Panasonic Healthcare Co., Ltd. Safety evaluations: Evaluate frequency of occurrence and seriousness of adverse events, problem of apparatus, and side effects.	—

Measure

Time frame

Assessments of effectiveness: Using samples from nasal cavity of patients of Alzheimer's disease and normal control; 1. Determine sampling sites such as olfactory cleft, middle nasal meatus, inferior nasal concha, and common nasal meatus for comparing AD patients with controls. 2. Examine a possibility of simultaneous detection of Abeta and tau with pretreatment method developed by Panasonic Healthcare Co., Ltd. Safety evaluations: Evaluate frequency of occurrence and seriousness of adverse events, problem of apparatus, and side effects.

—

Countries

Japan

Contacts

Public ContactIkuo Tooyama

Shiga University of Medical Science Molecular Neuroscience Research Center

kinchan@belle.shiga-med.ac.jp077-548-2330

Outcome results